

**COMPANY REGISTRATION NUMBER: 4364279**

**Biocensus Limited**

**Filleted Unaudited Financial Statements**

**31 January 2017**

# **Biocensus Limited**

## **Financial Statements**

**Year ended 31st January 2017**

### **Contents**

### **Page**

Statement of financial position

**1**

Notes to the financial statements

**3**

# Biocensus Limited

## Statement of Financial Position

**31 January 2017**

	Note	2017 £	£	2016 £	£
<b>Fixed assets</b>					
Tangible assets	5		<b>8,849</b>		10,083
<b>Current assets</b>					
Stocks		<b>88,586</b>		15,563	
Debtors	6	<b>143,791</b>		50,348	
Cash at bank and in hand		<b>40,291</b>		8,581	
		<b>272,668</b>		74,492	
<b>Creditors: amounts falling due within one year</b>	7	<b>250,422</b>		59,930	
<b>Net current assets</b>			<b>22,246</b>		14,562
<b>Total assets less current liabilities</b>			<b>31,095</b>		24,645
<b>Net assets</b>			<b>31,095</b>		24,645
<b>Capital and reserves</b>					
Called up share capital			<b>200</b>		200
Profit and loss account			<b>30,895</b>		24,445
<b>Shareholders funds</b>			<b>31,095</b>		24,645

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

For the year ending 31st January 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

# **Biocensus Limited**

## **Statement of Financial Position** *(continued)*

**31 January 2017**

These financial statements were approved by the board of directors and authorised for issue on 30 October 2017 , and are signed on behalf of the board by:

Dr G. Wilson

Dr T. Hounsome

Director

Director

Dr R. Delahay

Director

Company registration number: 4364279

# **Biocensus Limited**

## **Notes to the Financial Statements**

**Year ended 31st January 2017**

### **1. General information**

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Alex House, 260/8 Chapel Street, Salford, Manchester, M3 5JZ.

### **2. Statement of compliance**

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

### **3. Accounting policies**

#### **Basis of preparation**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

#### **Transition to FRS 102**

The entity transitioned from previous UK GAAP to FRS 102 as at 1st February 2015. Details of how FRS 102 has affected the reported financial position and financial performance is given in note 9.

#### **Revenue recognition**

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

#### **Income tax**

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

### **Tangible assets**

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

### **Depreciation**

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Fixtures and fittings	-	15% reducing balance
Equipment	-	20% reducing balance

### **Impairment of fixed assets**

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

### **Stocks**

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.

#### 4. Employee numbers

The average number of persons employed by the company during the year amounted to 4 (2016: 2 ).

#### 5. Tangible assets

	Fixtures and fittings £	Equipment £	Total £
<b>Cost</b>			
At 1st February 2016	6,382	12,230	<b>18,612</b>
Additions	644	–	<b>644</b>
	-----	-----	-----
<b>At 31st January 2017</b>	<b>7,026</b>	<b>12,230</b>	<b>19,256</b>
	-----	-----	-----
<b>Depreciation</b>			
At 1st February 2016	1,664	6,865	<b>8,529</b>
Charge for the year	805	1,073	<b>1,878</b>
	-----	-----	-----
<b>At 31st January 2017</b>	<b>2,469</b>	<b>7,938</b>	<b>10,407</b>
	-----	-----	-----
<b>Carrying amount</b>			
<b>At 31st January 2017</b>	<b>4,557</b>	<b>4,292</b>	<b>8,849</b>
	-----	-----	-----
At 31st January 2016	4,718	5,365	10,083
	-----	-----	-----

#### 6. Debtors

	2017 £	2016 £
Trade debtors	<b>133,443</b>	34,263
Other debtors	<b>10,348</b>	16,085
	-----	-----
	<b>143,791</b>	50,348
	-----	-----

#### 7. Creditors: amounts falling due within one year

	2017 £	2016 £
Trade creditors	<b>114,096</b>	20,538
Social security and other taxes	<b>63,246</b>	30,355
Other creditors	<b>73,080</b>	9,037
	-----	-----
	<b>250,422</b>	59,930
	-----	-----

#### 8. Related party transactions

The company was under the control of Dr T. Hounsome throughout the current period. Dr T. Hounsome is the managing director. No transactions with related parties were undertaken such as are required to be disclosed under FRS 102 1a.

#### 9. Transition to FRS 102

These are the first financial statements that comply with FRS 102. The company transitioned to FRS 102 on 1st February 2015.

No transitional adjustments were required in equity or profit or loss for the year.

